Therapeutic misconception—a false belief that individuals will benefit from participating in research—can bias informed consent. Ethics consultants can help by engaging participants’ and researchers’ understandings of risks and benefits and by asking good questions about the influences of researchers’ enthusiasm.
AMA J Ethics. 2018;20(11):E1100-1106. doi:
10.1001/amajethics.2018.1100.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Haley Moulton, Benjamin Moulton, JD, MPH, Tim Lahey, MD, MMSc, and Glyn Elwyn, MD, PhD, MSc
Shared decision making in research informed consent conversations is complex due to diverse and potentially divergent interests of investigators and patient-subjects.
AMA J Ethics. 2020;22(5):E365-371. doi:
10.1001/amajethics.2020.365.
Drs Katrina Bramstedt and Ana Iltis discuss the development of QoL assessment tools to help patient-subjects considering reconstructive transplantation.
This article considers that benefits of using humor in clinical settings come with risks of diminishing therapeutic capacity in patient-clinician relationships.
AMA J Ethics. 2020;22(7):E576-582. doi:
10.1001/amajethics.2020.576.
Joshua Nagler, MD, MHPEd and Rebekah Mannix, MD, MPH
Humor can help motivate positive interactions amidst fast-paced clinical encounters but can alienate colleagues when weaponized to promote assumed superiority of an individual or group.
AMA J Ethics. 2020;22(7):E583-587. doi:
10.1001/amajethics.2020.583.